These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1957127)

  • 1. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders.
    Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A
    Scand J Infect Dis; 1991; 23(4):413-20. PubMed ID: 1957127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
    Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
    Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
    Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
    J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience.
    Weiland O; Schvarcz R; Wejstål R; Norkrans G; Frydén A
    J Hepatol; 1990; 11 Suppl 1():S57-62. PubMed ID: 2127789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
    Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
    Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response.
    Reichard O; Glaumann H; Weiland O
    Scand J Infect Dis; 1994; 26(4):383-9. PubMed ID: 7984968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver.
    Reichen J; Bianchi L; Bühler H; Dolivo N; Gonvers JJ; Lavanchy D; Malé PJ; Renner EL; Solioz M; Schmid M; Zimmermann A
    J Hepatol; 1996 Sep; 25(3):275-82. PubMed ID: 8895005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C.
    Shindo M; Arai K; Okuno T
    J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
    Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
    J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study.
    Weiland O; Schvarcz R; Wejstål R; Norkrans G; Foberg U; Frydén A
    Scand J Infect Dis; 1989; 21(2):127-32. PubMed ID: 2499037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis.
    Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A
    Liver; 1991 Feb; 11(1):30-8. PubMed ID: 1646369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up evaluation in HCV chronic hepatitis treated with alpha-2b interferon. A comparison of two protocols.
    Budillon G; Cimino L; Del Vecchio Blanco C; Mazzacca G; Iaquinto G; D'Ascoli B; Lampasi F; Di Sapio M; Mattera D; Sapio D [corrected to Di Sapio M]
    Ital J Gastroenterol; 1994; 26(1):16-20. PubMed ID: 8025301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
    Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
    Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon.
    Castillo I; Bartolomé J; Navas S; Gonzalez S; Herrero M; Carreño V
    Hepatology; 1994 Jun; 19(6):1342-6. PubMed ID: 8188165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis.
    Saracco G; Rosina F; Torrani Cerenzia MR; Lattore V; Chiandussi L; Gallo V; Petrino R; De Micheli AG; Donegani E; Solinas A
    J Hepatol; 1990; 11 Suppl 1():S43-9. PubMed ID: 2127787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
    Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
    Blood; 1991 Oct; 78(7):1672-7. PubMed ID: 1912556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.
    Causse X; Godinot H; Chevallier M; Chossegros P; Zoulim F; Ouzan D; Heyraud JP; Fontanges T; Albrecht J; Meschievitz C
    Gastroenterology; 1991 Aug; 101(2):497-502. PubMed ID: 1906028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.